Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Genitourinary" returned 12 results:


Phase II Trial to Evaluate Benefit of Early Switch from first-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the opposite sequence, exploring molecular markers and mechanisms of taxane resistance in men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have not received prior chemotherapy
Principal Investigator(s): Che-Kai Tsao

Multi-center Phase 2 Trial of Single-agent Amrubicin as second-line therapy in patients with Advanced/Metastatic Refractory Urothelial Carcinoma
Principal Investigator(s): Matthew Galksy

Metformin - Rising PSA Remote Trial (M-RePoRT)
Principal Investigator(s): Dr. Matthew Galsky

A Randomized, Phase 2, Open Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
Principal Investigator(s): Simon J. Hall

A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Principal Investigator(s): Dr. William Oh

Phase II Trial of Everolimus or Everolimus plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma
Principal Investigator(s): Matthew Galsky

A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer
Principal Investigator(s): Matthew Galsky

Phase II Trial of Gemcitabine, Cisplatin, plus Ipilimumab as First-line Treatment for Patients with Metastatic Urothelial Carcinoma
Principal Investigator(s): Matthew Galsky

Metformin - Rising PSA Remote Trial (M-RePoRT)
Principal Investigator(s): Dr. Matthew Galsky

An International Phase 3, Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
Principal Investigator(s): Michael A. Palese

A Phase I, open-label, multicenter, dose escalation study of oral BGJ398, a pan FGFR kinase inhibitor, in adult patients with advanced solid malignancies
Principal Investigator(s): Dr. Matthew Galsky

A Pilot Study of Abiraterone Acetate in African American/Black Patients with Castration Resistant Prostate Cancer
Principal Investigator(s): Matthew Galsky